ClinicalTrials.gg
CompletedNCT04570384Updated Feb 22, 2023Results posted

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

A Phase 2 interventional study of L-Citrulline and Placebo in Acute Hypoxemic Respiratory Failure, sponsored by Asklepion Pharmaceuticals, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Asklepion Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Enrollment
96th of 253
65 · median 42
Started
2020
with 41 others
Phase 2
28 of 349
3 open now
Registered
254th of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 96th largest by enrollment of the 253 interventional ones that give a count, is one of 42 that started in 2020, is one of 28 in phase 2, and was the 254th registered.

Respiratory Insufficiency

1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients with COVID-19 (SARS-CoV2) Illness. To evaluate safety and efficacy of a bolus loading dose and continuous intravenous infusion of L-Citrulline compared to placebo in patients hospitalized with COVID-19 infection (SARS-CoV-2).

Read the detailed description

Intravenous L-citrulline (Turnobi) administration will safely restore the homeostasis of nitric oxide synthase by increasing both plasma citrulline and arginine levels. Investigators also reason that restoration of citrulline/arginine balance through citrulline administration will safely re-establish homeostasis of NOS, lower oxidative stress, and reduce inflammation, thereby delaying and potentially preventing the need for invasive mechanical ventilation in participants hospitalized with COVID-19 infection (SARS-CoV-2). The body lives in a delicate balance of homeostasis. The urea/NO cycle plays a critical role in maintaining redox homeostasis and as such, also plays a role in regulating inflammation. The biochemical relationships are complex and depend on inter-organ transfer, membrane transport, and intracellular compartmentation. However, data above demonstrate that citrulline, arginine, and NO are critical in maintaining this homeostasis through their regulation of NOS. Inflammation, especially from infection, results in decreased activity of CPS1 and increased activity of arginase, which decreases levels of both citrulline and arginine. These decreased levels result in dysregulated and uncoupled NOS, which drives both overexuberant NO production and formation of ROS. Both the NO production and ROS further exacerbate the inflammatory cascade, resulting in other organ dysfunctions, including acute lung injury. Both inflammation and oxidative stress have been shown to be driving forces for the development of ALI and regulated NOS function is vital to reducing both. Both plasma citrulline and arginine are deficient in sepsis and levels are inversely associated with development of ALI. Furthermore, citrulline replacement safely increases plasma levels of both citrulline and arginine in healthy volunteers, BMT patients, adults with sepsis, children with sickle cell disease, and children after congenital heart surgery. It seems highly likely that citrulline therapy in the setting of COVID-19 (SARS-CoV2) induced acute hypoxemic respiratory illness will safely increase citrulline and arginine levels and help re-establish NOS homeostasis, resulting in NO production in compartments that are more homeostatically appropriate so as to reduce pulmonary vascular resistance and enhance coupling of NOS to minimize superoxide production thus reducing free radical mediated ALI.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years.
  2. Clinical evidence of COVID-19 (SARS-CoV2) infection, defined as a positive COVID-19 laboratory test plus evidence of an acute hypoxemic respiratory illness requiring oxygen.
  3. Admitted and transferred to floor without intubation.

Exclusion criteria

Exclusion Criteria:

  1. No consent/inability to obtain consent
  2. Patient, surrogate, or physician not committed to full support
  3. Malignant or other irreversible condition and estimated 28-day mortality ≥ 50%
  4. Moribund patient not expected to survive 48 hours (as defined by primary medical team) from start of study infusion
  5. End-stage Liver Disease as defined by Score > 9
  6. Currently enrolled in, or participated in another study of an compound within the last 30 days
  7. Pregnant female, or female who is breast feeding
  8. Allergy to L-citrulline or arginine or any citrulline- or arginine-containing product
  9. Patient not otherwise suitable for the study in the opinion of any of the investigators
  10. Requirement for intubation and invasive mechanical ventilation before study enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    IV L-Citrulline (Turnobi) Arm

    Patients randomized to citrulline will receive an initial intravenous bolus of 20 mg/kg (to a maximum of 1500 mg) L-citrulline over 10 minutes. The study solution will be prepared as a 5% isotonic solution (50 mg/mL) in 5% dextrose water. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9 mg/kg (max 700 mg) per hour will be administered through a dedicated intravenous line or port of a multi-lumen catheter.

    Drug: L-Citrulline

  • Placebo comparator
    Placebo Arm

    Patients randomized to placebo arm will receive an infusion of 5% dextrose water matched for volume and color to the citrulline infusion. The placebo infusion will consist of an initial iv bolus (up to 30 mL) over 10 minutes followed by a continuous infusion of 5% dextrose water (about 15 mL/hr). The initial bolus and subsequent infusion will be administered through a dedicated intravenous line or port of a multi-lumen catheter.

    Drug: Placebo

Interventions

  • L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.

    Also known as: L-CIT, CIT

  • DrugPlacebo

    Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.

06

What researchers measure

Primary outcomes

  1. Time to Non-invasive/Invasive Mechanical Ventilation

    Time in hours from the initiation of the treatment until mechanical ventilation is required, whether non-invasive (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) or invasive (i.e., requiring intubation).

    Time frame: From the start of infusion to Day 60 Follow-up

  2. Time to Non-invasive Mechanical Ventilation

    Time in hours from the initiation of the treatment until non-invasive mechanical ventilation is required (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) .

    Time frame: From the start of infusion to Day 60 Follow-up

  3. Time to Invasive Mechanical Ventilation

    Time in hours from the initiation of the treatment until intubation for invasive mechanical ventilation is required.

    Time frame: From the start of infusion to Day 60 Follow-up

  4. Systolic Blood Pressure

    Systolic blood pressure measured in mmHg

    Time frame: Day 1

  5. Diastolic Blood Pressure

    Diastolic blood pressure measured in mmHg

    Time frame: Day 1

  6. Mean Arterial Pressure

    Mean arterial pressure measured in mmHg

    Time frame: Day 1

Secondary outcomes

  1. Blood Levels of Arginine

    Plasma levels of arginine

    Time frame: Plasma levels of arginine at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment

  2. Blood Levels of Citrulline

    Plasma levels of citrulline

    Time frame: Plasma levels of citrulline at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment

  3. Evaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation

    Total length of time of any mechanical ventilation

    Time frame: Day 1 through Day 60 Follow Up

  4. Evaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality

    To evaluate the effect of intravenous L-Citrulline compared to placebo on Hospital all-cause mortality

    Time frame: Day 1 through day 12

  5. Percentage of Patients Admitted to Intensive Care

    Time frame: Day 1 through Day 12 (DC)

  6. Duration of Intensive Care Unit (ICU) Stay

    Length of ICU stay (days)

    Time frame: From admission to ICU until discharge or death

  7. Duration of Hospitalisation

    Length of hospital stay (days)

    Time frame: From admission to hospital until discharge or death

  8. Number of Patients Requiring Intubation

    Percentage of patients requiring any mechanical ventilation, invasive mechanical ventilation and non-invasive mechanical ventilation.

    Time frame: From the start of infusion to Day 60 Follow-up

  9. Overall Duration of Mechanical Ventilation

    Total time on any mechanical ventilation, invasive mechanical ventilation, non-invasive mechanical ventilation and nasal cannula

    Time frame: From the start of infusion to Day 60 Follow-up

07

Results

Posted Feb 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneIV L-Citrulline (Turnobi) ArmPlacebo Arm
Started3332
Completed2223
Not completed119
Withdrew: Adverse event21
Withdrew: Death25
Withdrew: Lost to follow-up10
Withdrew: Other10
Withdrew: Protocol violation01
Withdrew: Sponsor decision10
Withdrew: Withdrawal by subject42

Outcome measures

PrimaryTime to Non-invasive/Invasive Mechanical Ventilation

Time in hours from the initiation of the treatment until mechanical ventilation is required, whether non-invasive (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) or invasive (i.e., requiring intubation).

Time frame:
From the start of infusion to Day 60 Follow-up
Reported as:
Mean · Hours
Time to Non-invasive/Invasive Mechanical Ventilation
HoursIV L-Citrulline (Turnobi) ArmPlacebo Arm
Time to Non-invasive/Invasive Mechanical Ventilation96.65 ± 143.7370.49 ± 62.44
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Log Rank · p = 0.782 · Hazard ratio (hr): 1.14 · 95% CI 0.45 to 2.86
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Regression, Logistic · p = 0.668 · Odds ratio (or): 1.25 · 95% CI 0.46 to 3.40
PrimaryTime to Non-invasive Mechanical Ventilation

Time in hours from the initiation of the treatment until non-invasive mechanical ventilation is required (e.g., high flow nasal cannula, bilevel positive airway pressure, oxygen therapy) .

Time frame:
From the start of infusion to Day 60 Follow-up
Reported as:
Mean · Hours
Time to Non-invasive Mechanical Ventilation
HoursIV L-Citrulline (Turnobi) ArmPlacebo Arm
Time to Non-invasive Mechanical Ventilation66.17 ± 105.40105.70 ± 108.90
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Log Rank · p = 0.360 · Hazard ratio (hr): 1.58 · 95% CI 0.59 to 4.22
PrimaryTime to Invasive Mechanical Ventilation

Time in hours from the initiation of the treatment until intubation for invasive mechanical ventilation is required.

Time frame:
From the start of infusion to Day 60 Follow-up
Reported as:
Mean · Hours
Time to Invasive Mechanical Ventilation
HoursIV L-Citrulline (Turnobi) ArmPlacebo Arm
Time to Invasive Mechanical Ventilation290.01 ± 254.31148.07 ± 108.08
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Log Rank · p = 0.285 · Hazard ratio (hr): 0.49 · 95% CI 0.13 to 1.83
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Regression, Logistic · p = 0.471 · Odds ratio (or): 0.60 · 95% CI 0.15 to 2.41
PrimarySystolic Blood Pressure

Systolic blood pressure measured in mmHg

Time frame:
Day 1
Reported as:
Mean · Millimeters of mercury
Systolic Blood Pressure
Millimeters of mercuryIV L-Citrulline (Turnobi) ArmPlacebo Arm
Systolic Blood Pressure118.63 ± 14.69130.19 ± 15.71
PrimaryDiastolic Blood Pressure

Diastolic blood pressure measured in mmHg

Time frame:
Day 1
Reported as:
Mean · Millimeters of mercury
Diastolic Blood Pressure
Millimeters of mercuryIV L-Citrulline (Turnobi) ArmPlacebo Arm
Diastolic Blood Pressure73.58 ± 10.0679.74 ± 13.13
PrimaryMean Arterial Pressure

Mean arterial pressure measured in mmHg

Time frame:
Day 1
Reported as:
Mean · Millimeters of mercury
Mean Arterial Pressure
Millimeters of mercuryIV L-Citrulline (Turnobi) ArmPlacebo Arm
Mean Arterial Pressure87.58 ± 10.0394.30 ± 13.49
SecondaryBlood Levels of Arginine

Plasma levels of arginine

Time frame:
Plasma levels of arginine at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment
Reported as:
Mean · µmol/L
Blood Levels of Arginine
µmol/LIV L-Citrulline (Turnobi) ArmPlacebo Arm
Hour 067.6 ± 28.2767.88 ± 29.51
Hour 292.57 ± 30.8471.51 ± 29.15
Hour 12128.11 ± 41.375.7 ± 24.54
Day 2142.02 ± 54.5182.19 ± 26.33
Day 4152.00 ± 66.779.66 ± 22.84
Day 6169.33 ± 113.6270.78 ± 19.46
Day 8167.64 ± 82.581.79 ± 32.28
Day 10160.02 ± 83.3983.9 ± 37.36
SecondaryBlood Levels of Citrulline

Plasma levels of citrulline

Time frame:
Plasma levels of citrulline at 0, 2 and 12 hours, and 2, 4, 6, 8, 10 days after initiation of treatment
Reported as:
Mean · µmol/L
Blood Levels of Citrulline
µmol/LIV L-Citrulline (Turnobi) ArmPlacebo Arm
Hour 024.64 ± 25.9118.08 ± 13.7
Hour 21094.41 ± 2463.9718.39 ± 14.08
Hour 12997.61 ± 2133.0721.84 ± 16.14
Day 2278.2 ± 353.3224.68 ± 27.57
Day 4626.33 ± 1562.9520.53 ± 15.84
Day 6185.14 ± 68.6320.96 ± 10.16
Day 8192.72 ± 127.7224.84 ± 9.64
Day 10206.26 ± 135.9424.56 ± 11.46
SecondaryEvaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation

Total length of time of any mechanical ventilation

Time frame:
Day 1 through Day 60 Follow Up
Reported as:
Mean · Hours
Evaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation
HoursIV L-Citrulline (Turnobi) ArmPlacebo Arm
Evaluate the Effect of Intravenous L-Citrulline Compared to Placebo as Measured by the Total Length of All Mechanical Ventilation270.91 ± 304.03451.87 ± 503.68
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Zero-inflated negative binomial analyses · p = 0.668 · Odds ratio, log: 0.81 · 95% CI 0.30 to 2.20
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Zero-inflated negative binomial analyses · p = 0.437 · Incidence rate ratio: 0.66 · 95% CI 0.23 to 1.90
SecondaryEvaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality

To evaluate the effect of intravenous L-Citrulline compared to placebo on Hospital all-cause mortality

Time frame:
Day 1 through day 12
Reported as:
Count of participants · Participants
Evaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality
ParticipantsIV L-Citrulline (Turnobi) ArmPlacebo Arm
Evaluate the Effect of IV L-Citrulline to Placebo for Hospital All Cause Mortality25
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Regression, Logistic · p = 0.232 · Odds ratio (or): 0.35 · 95% CI 0.06 to 1.97
SecondaryPercentage of Patients Admitted to Intensive Care
Time frame:
Day 1 through Day 12 (DC)
Reported as:
Count of participants · Participants
Percentage of Patients Admitted to Intensive Care
ParticipantsIV L-Citrulline (Turnobi) ArmPlacebo Arm
Percentage of Patients Admitted to Intensive Care1213
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Regression, Logistic · p = 0.729 · Odds ratio (or): 0.84 · 95% CI 0.31 to 2.28
SecondaryDuration of Intensive Care Unit (ICU) Stay

Length of ICU stay (days)

Time frame:
From admission to ICU until discharge or death
Reported as:
Mean · Days
Duration of Intensive Care Unit (ICU) Stay
DaysIV L-Citrulline (Turnobi) ArmPlacebo Arm
Duration of Intensive Care Unit (ICU) Stay14.83 ± 12.2917.31 ± 18.87
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Zero-inflated negative binomial analyses · p = 0.706 · Odds ratio, log: 1.22 · 95% CI 0.43 to 3.44
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Zero-inflated negative binomial analyses · p = 0.788 · Incidence rate ratio: 1.12 · 95% CI 0.49 to 2.56
SecondaryDuration of Hospitalisation

Length of hospital stay (days)

Time frame:
From admission to hospital until discharge or death
Reported as:
Mean · Days
Duration of Hospitalisation
DaysIV L-Citrulline (Turnobi) ArmPlacebo Arm
Duration of Hospitalisation10.61 ± 12.7411.88 ± 14.29
Statistical analysis
  • IV L-Citrulline (Turnobi) Arm vs Placebo Arm · Negative binomial analysis · p = 0.834 · Incidence rate ratio: 1.08 · 95% CI 0.52 to 2.25
SecondaryNumber of Patients Requiring Intubation

Percentage of patients requiring any mechanical ventilation, invasive mechanical ventilation and non-invasive mechanical ventilation.

Time frame:
From the start of infusion to Day 60 Follow-up
Reported as:
Count of participants · Participants
Number of Patients Requiring Intubation
ParticipantsIV L-Citrulline (Turnobi) ArmPlacebo Arm
Non-invasive/invasive mechanical ventilation1412
Non-invasive mechanical ventilation1210
Invasive mechanical ventilation46
SecondaryOverall Duration of Mechanical Ventilation

Total time on any mechanical ventilation, invasive mechanical ventilation, non-invasive mechanical ventilation and nasal cannula

Time frame:
From the start of infusion to Day 60 Follow-up
Reported as:
Mean · Hours
Overall Duration of Mechanical Ventilation
HoursIV L-Citrulline (Turnobi) ArmPlacebo Arm
Total time on mechanical ventilation239.31 ± 243.08222.08 ± 370.90
Total time of non-invasive mechanical ventilation224.64 ± 254.22219.27 ± 309.40
Total time of invasive mechanical ventilation274.27 ± 158.86538.28 ± 469.21
Total time on Nasal Cannula239.31 ± 243.08222.08 ± 370.90

Adverse events

Collected over Adverse events data were collected from the time that the participant was first administered the study infusion (study hour = 0) until Day 10. Adverse events spontaneously reported to the investigator or observed by the investigator after Day 10 until Day 60 Follow Up were also collected and recorded.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV L-Citrulline (Turnobi) Arm2/33 (6.1%)6/33 (18.2%)11/33 (33.3%)
Placebo Arm5/32 (15.6%)10/32 (31.3%)11/32 (34.4%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventIV L-Citrulline (Turnobi) ArmPlacebo Arm
PneumothoraxRespiratory, thoracic and mediastinal disorders0/333/32
Cardiac arrestCardiac disorders0/332/32
DyspnoeaRespiratory, thoracic and mediastinal disorders2/330/32
Intracranial hemorrhageVascular disorders1/331/32
Acute Respiratory Distress Syndrome, PneumoniaRespiratory, thoracic and mediastinal disorders0/331/32
Acute kidney injury; renal tubular necrosisRenal and urinary disorders0/331/32
Brain InjuryNervous system disorders0/331/32
Cardiac valve vegetationCardiac disorders0/331/32
Cardio-respiratory ArrestRespiratory, thoracic and mediastinal disorders0/331/32
Cardiac Failure CongestiveCardiac disorders0/331/32
Most frequent other events
Showing 10 of 31
Most frequent other events
EventIV L-Citrulline (Turnobi) ArmPlacebo Arm
Infusion Site ReactionGeneral disorders3/332/32
Acute kidney injuryRenal and urinary disorders0/332/32
Clostridium Difficile InfectionInfections and infestations2/330/32
Deep Vein ThrombosisVascular disorders2/331/32
Urinary Tract InfectionInfections and infestations2/330/32
Chest PainGeneral disorders0/331/32
ConstipationGastrointestinal disorders0/331/32
CoughRespiratory, thoracic and mediastinal disorders0/331/32
DehydrationMetabolism and nutrition disorders0/331/32
DyspnoeaRespiratory, thoracic and mediastinal disorders0/331/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)IV L-Citrulline (Turnobi) ArmPlacebo ArmTotal
Mean50.30 ± 11.0451.13 ± 10.3450.71 ± 10.63
Age, Customized
Age, Customized(Participants)IV L-Citrulline (Turnobi) ArmPlacebo ArmTotal
18-49 years131225
50-65 years202040
Sex: Female, Male
Sex: Female, Male(Participants)IV L-Citrulline (Turnobi) ArmPlacebo ArmTotal
Female16925
Male172340
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV L-Citrulline (Turnobi) ArmPlacebo ArmTotal
Hispanic or Latino325
Not Hispanic or Latino292655
Unknown or Not Reported145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV L-Citrulline (Turnobi) ArmPlacebo ArmTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American181735
White121224
More than one race000
Unknown or Not Reported235
08

Study locations

1 site
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Aug 2021, 10 months.

Results were first posted in Feb 2023, 1 year 5 months after primary completion.

Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2020
First posted
Sep 30, 2020
StartActual
Oct 15, 2020
Primary completionActual
Aug 30, 2021
CompletionActual
Sep 30, 2021
Results first posted
Feb 22, 2023
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04570384
Lead sponsor
Asklepion Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Oct 15, 2020
Primary completion
Aug 30, 2021
Completion
Sep 30, 2021
Results posted
Feb 22, 2023
Last update
Feb 22, 2023

Study contacts

Gurdyal Kalsi, MD, MFPM
study director · Asklepion Pharmaceuticals, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citrulline

Start the discussion